Humana Inc. v. Handa Pharmaceuticals, LLC

CourtDistrict Court, N.D. California
DecidedAugust 15, 2023
Docket4:23-cv-01550
StatusUnknown

This text of Humana Inc. v. Handa Pharmaceuticals, LLC (Humana Inc. v. Handa Pharmaceuticals, LLC) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Humana Inc. v. Handa Pharmaceuticals, LLC, (N.D. Cal. 2023).

Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 HUMANA INC., Case No. 23-cv-01550-DMR 8 Plaintiff, Case No. 23-cv-1553-DMR

9 v. ORDER ON MOTIONS TO REMAND 10 HANDA PHARMACEUTICALS, LLC, Re: Dkt. No. 15 11 Defendant.

12 Plaintiffs Humana Inc. (“Humana”) and Aetna Inc. (“Aetna”) filed motions to remand that 13 turn primarily on whether the forum-defendant rule, 28 U.S.C. § 1441(b)(2), prohibits a forum 14 defendant from removing a case before it has been served. This matter is suitable for resolution 15 without a hearing. Civ. L.R. 7-1(b). For the reasons below, the motions to remand are denied. 16 I. BACKGROUND 17 The procedural history bears more on these motions than the substance of Plaintiffs’ 18 complaints. The court limits the description of the cases accordingly. 19 Plaintiffs Humana and Aetna filed their original complaints in separate lawsuits in San 20 Francisco Superior Court against Defendant Handa Pharmaceuticals, LLC (“Handa”), on March 21 28 and March 30, 2023, respectively. [23-cv-01550 (“Humana Action”), Docket No. 1-1; 23-cv- 22 01553 (“Aetna Action”), Docket No. 1-1 (together “Compls.”).] The complaints allege state law 23 claims for 1) conspiracy to monopolize; 2) combination and conspiracy in restraint of trade; 3) 24 unfair or deceptive trade practices; and 4) unjust enrichment. Compls. ¶¶ 173-225. 25 Handa removed both cases on March 31, 2023 – before Humana served Handa on April 6, 26 2023, and Aetna served Handa on April 7, 2023. [Humana Action, Docket Nos. 1 (Humana’s 27 Notice of Removal); 14 (Stipulation to Extend Defendant’s Time to Respond to the Complaints); 1 Time to Respond to the Complaints).] Humana asserts that it unsuccessfully attempted to serve 2 Handa prior to removal, on March 30, 2023, at the address listed for Handa’s agent for service of 3 process on the California Secretary of State website. [Docket No. 15-1 (Matthew S. Weiler Decl., 4 Apr. 28, 2023) ¶¶ 8, 9.] 5 The court related the cases on April 19, 2023. [Humana and Aetna Actions, Docket No. 6 11.] Plaintiffs now move to remand the cases, arguing that because Handa is a resident of 7 California, removal based on diversity jurisdiction is barred by the forum defendant rule, 28 8 U.S.C. § 1441(b)(2). [Humana and Aetna Actions, Docket Nos. 15 (“Mot.”); 20 (“Reply”).] In 9 the alternative, Plaintiffs claim that removal is improper because there is no federal question 10 jurisdiction. Handa opposes. [Humana and Aetna Actions, Docket No. 19 (“Opp’n”).] 11 II. LEGAL STANDARD 12 Under 28 U.S.C. § 1441(a), a defendant may remove to federal court any matter that 13 originally could have been filed in federal court. Caterpillar Inc. v. Williams, 482 U.S. 386, 392 14 (1987). Federal courts are courts of limited jurisdiction and possess subject matter jurisdiction in 15 civil cases based only on federal question or diversity jurisdiction. Id.; see 28 U.S.C. §§ 1331, 16 1332. The removing defendant bears the burden of establishing that removal was proper. United 17 Computer Sys., Inc. v. AT & T Corp., 298 F.3d 756, 763 (9th Cir. 2002). “If at any time before 18 final judgment it appears that the district court lacks subject matter jurisdiction, the case shall be 19 remanded.” 28 U.S.C. § 1447(c); see also Gaus v. Miles, Inc., 980 F.2d 564, 566 (9th Cir. 1992) 20 (stating that the removal statute is “strictly construe[d]” and “[f]ederal jurisdiction must be 21 rejected if there is any doubt as to the right of removal in the first instance.”). 22 III. DISCUSSION 23 The court first addresses whether Handa properly removed the cases on the basis of 24 diversity jurisdiction.1 25 1 Handa argues that, as a threshold matter, the court should elect to transfer these cases to the 26 District of Delaware before deciding the question of remand. Opp’n at 9. While courts are generally free to rule on remand and transfer motions in any order, see Burse v. Purdue Pharma 27 Co., No. C-04-594 SC, 2004 WL 1125055, at *1 (N.D. Cal. May 3, 2004), none of the cases cited 1 The parties do not appear to dispute that the court has diversity jurisdiction pursuant to 28 2 U.S.C. § 1332 because the parties are completely diverse and the amount in controversy exceeds 3 $75,000.2 Instead, Plaintiffs contend that Handa, as a California citizen, cannot remove the 4 complaints on the basis of diversity jurisdiction because of the forum defendant rule. Handa 5 disagrees, contending that removal is not barred because it had not been served when the cases 6 were removed. 7 The forum defendant rule provides that “[a] civil action otherwise removable solely on the 8 basis of the jurisdiction under section 1332(a) of this title may not be removed if any of the parties 9 in interest properly joined and served as defendants is a citizen of the State in which such action is 10 brought.” 28 U.S.C. § 1441(b)(2). The rule “confines removal on the basis of diversity 11 jurisdiction to instances where no defendant is a citizen of the forum state.” Lively v. Wild Oats 12 Mkts., Inc., 456 F.3d 933, 939 (9th Cir. 2006); see also Spencer v. U.S. Dist. Court for N. Dist. of 13 Cal., 393 F.3d 867, 870 (9th Cir. 2004) (holding that “the presence of a local defendant at the time 14 removal is sought bars removal”). 15 At issue is what is sometimes referred to as “snap removal” – “[t]he practice of 16 circumventing application of the forum-defendant rule by removing before defendants are served.” 17 Lam Sing v. Sunrise Senior Mgmt., Inc., No. C 23-00733 WHA, 2023 WL 3686251, at *3 (N.D. 18 Cal. May 26, 2023). As the court explained in Lam Sing, “[s]nap removal may apply in a situation 19 where a defendant “was able to remove . . . and argue against application of the forum defendant 20 rule because it managed to remove the case before [plaintiff] was able to serve it.” Id. (citing 21 Aetna Inc. v. Gilead Scis., Inc., 599 F. Supp. 3d 913, 918 (N.D. Cal. 2022)). 22 Plaintiffs’ arguments shifted in the course of briefing. Their opening brief makes four 23 arguments in support of remand. First, Plaintiffs assert a legal argument that even if defendants 24 [Docket No. 14.] Nothing prevented Handa from filing a motion to transfer and in fact, it 25 voluntarily agreed that transfer should follow this remand motion. Id. For these reasons, Handa’s request is denied. 26

2 Humana is a Delaware corporation with its principal place of business in Kentucky. [Docket 1-1 27 ¶ 32.] Aetna is a holding company headquartered in Connecticut and incorporated under the laws 1 are served after removal, the forum defendant rule prohibits removal. Second, Plaintiffs contend 2 that as a factual matter, Humana served Handa prior to removal for purposes of the forum 3 defendant rule; even though Handa was not formally served, Humana attempted to serve Handa 4 through its registered agent on March 30, 2023, the day before removal.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Caterpillar Inc. v. Williams
482 U.S. 386 (Supreme Court, 1987)
Demarest v. Manspeaker
498 U.S. 184 (Supreme Court, 1991)
Williams v. Perez
110 F. Supp. 3d 1 (District of Columbia, 2015)
Texas Brine Company, L.L.C. v. Amer Arbitration As
955 F.3d 482 (Fifth Circuit, 2020)
McCall v. Scott
239 F.3d 808 (Sixth Circuit, 2001)
Little v. Wyndham Worldwide Operations, Inc.
251 F. Supp. 3d 1215 (M.D. Tennessee, 2017)
Gibbons v. Bristol-Myers Squibb Co.
919 F.3d 699 (Second Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Humana Inc. v. Handa Pharmaceuticals, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/humana-inc-v-handa-pharmaceuticals-llc-cand-2023.